A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma

Published:2023-04 Issue:4 Volume:26 Page:465-476
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Cope Shannon,Chan Keith,Campbell Harlan,Chen Jenny,Borrill John,May Jessica R.,Malcolm William,Branchoux Sebastien,Kupas Katrin,Jansen Jeroen P.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference65 articles.

1. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials;Moher;J Clin Epidemiol,2010

2. Review of the reporting of survival analyses within randomised controlled trials and the implications for meta-analysis;Batson;PLoS One,2016

3. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome;Royston;BMC Med Res Methodol,2013

4. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

5. Statistical inference methods for two crossing survival curves: a comparison of methods;Li;PLoS One,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian pairwise meta‐analysis of time‐to‐event outcomes in the presence of non‐proportional hazards: A simulation study of flexible parametric, piecewise exponential and fractional polynomial models;Research Synthesis Methods;2024-05-21

2. Conduct and reporting of multivariate network meta-analyses: a scoping review;Journal of Clinical Epidemiology;2024-02

3. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective;Journal of Medical Economics;2023-09-09

4. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma;Journal of Comparative Effectiveness Research;2023-08